Estrogen signalling and Alzheimer's disease: Decoding molecular mechanisms for therapeutic breakthrough

In females, Alzheimer's disease (AD) incidences increases as compared to males due to estrogen deficiency after menopause. Estrogen therapy is the mainstay therapy for menopause and associated complications. Estrogen, a hormone with multifaceted physiological functions, has been implicated in A...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The European journal of neuroscience 2024-07, Vol.60 (1), p.3466-3490
Hauptverfasser: Rishabh, Rohilla, Manni, Bansal, Seema, Bansal, Nitin, Chauhan, Samrat, Sharma, Sheenam, Goyal, Navjyoti, Gupta, Sumeet
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 3490
container_issue 1
container_start_page 3466
container_title The European journal of neuroscience
container_volume 60
creator Rishabh
Rohilla, Manni
Bansal, Seema
Bansal, Nitin
Chauhan, Samrat
Sharma, Sheenam
Goyal, Navjyoti
Gupta, Sumeet
description In females, Alzheimer's disease (AD) incidences increases as compared to males due to estrogen deficiency after menopause. Estrogen therapy is the mainstay therapy for menopause and associated complications. Estrogen, a hormone with multifaceted physiological functions, has been implicated in AD pathophysiology. Estrogen plays a crucial role in amyloid precursor protein (APP) processing and overall neuronal health by regulating various factors such as brain‐derived neurotrophic factor (BDNF), intracellular calcium signalling, death domain‐associated protein (Daxx) translocation, glutamatergic excitotoxicity, Voltage‐Dependent Anion Channel, Insulin‐Like Growth Factor 1 Receptor, estrogen‐metabolising enzymes and apolipoprotein E (ApoE) protein polymorphisms. All these factors impact the physiology of postmenopausal women. Estrogen replacement therapies play an important treatment strategy to prevent AD after menopause. However, use of these therapies may lead to increased risks of breast cancer, venous thromboembolism and cardiovascular disease. Various therapeutic approaches have been used to mitigate the effects of estrogen on AD. These include hormone replacement therapy, Selective Estrogen Receptor Modulators (SERMs), Estrogen Receptor Beta (ERβ)‐Selective Agonists, Transdermal Estrogen Delivery, Localised Estrogen Delivery, Combination Therapies, Estrogen Metabolism Modulation and Alternative Estrogenic Compounds like genistein from soy, a notable phytoestrogen from plant sources. However, mechanism via which these approaches modulate AD in postmenopausal women has not been explained earlier thoroughly. Present review will enlighten all the molecular mechanisms of estrogen and estrogen replacement therapies in AD. Along‐with this, the association between estrogen, estrogen‐metabolising enzymes and ApoE protein polymorphisms will also be discussed in postmenopausal AD. Estrogen plays an important role in maintaining various physiological functions of the women's body. Estrogen deficiency due to oxidative stress, hormonal disbalance and disturbance in molecular signalling pathways such as intracellular calcium, Daxx translocation, glutaminergic excitotoxicity, voltage dependent anion and insulin like growth factor 1 receptor leads to the development of neurodegenerative diseases including Alzheimer's disease (AD). Molecular signalling works by altering the expression of estrogen receptors such as ERα & ERβ and through estrogen response elements. Enormou
doi_str_mv 10.1111/ejn.16360
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_3053976209</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3075798527</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3130-c59b689de95e4f78e4bef3481aca81f8be785526fa4b32c41e3ae3d05e4cd6063</originalsourceid><addsrcrecordid>eNp10EtLxDAUhuEgio6XhX9AAi7URTVpmjR1JzreEN0ouCtpetpmTJsxaRH99XYcdSF4Nmfz8C1ehHYpOabjncCsO6aCCbKCJjQRJMq4kKtoQjLOIknF8wbaDGFGCJEi4etog8k0FqlIJqieht67GjocTN0pa01XY9WV-Mx-NGBa8AcBlyaACnCKL0C7ciFaZ0EPVnncgm5UZ0IbcOU87hvwag5DbzQuPKiXvvFuqJtttFYpG2Dn-2-hp8vp4_l1dPdwdXN-dhdpRhmJNM8KIbMSMg5JlUpICqhYIqnSStJKFpBKzmNRqaRgsU4oMAWsJKPWpSCCbaHD5e7cu9cBQp-3JmiwVnXghpAzwlmWiphkI93_Q2du8GODhUp5mkkep6M6WirtXQgeqnzuTav8e05Jvqifj_Xzr_qj3fteHIoWyl_5k3sEJ0vwZiy8_7-UT2_vl5OfDyCPrw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3075798527</pqid></control><display><type>article</type><title>Estrogen signalling and Alzheimer's disease: Decoding molecular mechanisms for therapeutic breakthrough</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Rishabh ; Rohilla, Manni ; Bansal, Seema ; Bansal, Nitin ; Chauhan, Samrat ; Sharma, Sheenam ; Goyal, Navjyoti ; Gupta, Sumeet</creator><creatorcontrib>Rishabh ; Rohilla, Manni ; Bansal, Seema ; Bansal, Nitin ; Chauhan, Samrat ; Sharma, Sheenam ; Goyal, Navjyoti ; Gupta, Sumeet</creatorcontrib><description>In females, Alzheimer's disease (AD) incidences increases as compared to males due to estrogen deficiency after menopause. Estrogen therapy is the mainstay therapy for menopause and associated complications. Estrogen, a hormone with multifaceted physiological functions, has been implicated in AD pathophysiology. Estrogen plays a crucial role in amyloid precursor protein (APP) processing and overall neuronal health by regulating various factors such as brain‐derived neurotrophic factor (BDNF), intracellular calcium signalling, death domain‐associated protein (Daxx) translocation, glutamatergic excitotoxicity, Voltage‐Dependent Anion Channel, Insulin‐Like Growth Factor 1 Receptor, estrogen‐metabolising enzymes and apolipoprotein E (ApoE) protein polymorphisms. All these factors impact the physiology of postmenopausal women. Estrogen replacement therapies play an important treatment strategy to prevent AD after menopause. However, use of these therapies may lead to increased risks of breast cancer, venous thromboembolism and cardiovascular disease. Various therapeutic approaches have been used to mitigate the effects of estrogen on AD. These include hormone replacement therapy, Selective Estrogen Receptor Modulators (SERMs), Estrogen Receptor Beta (ERβ)‐Selective Agonists, Transdermal Estrogen Delivery, Localised Estrogen Delivery, Combination Therapies, Estrogen Metabolism Modulation and Alternative Estrogenic Compounds like genistein from soy, a notable phytoestrogen from plant sources. However, mechanism via which these approaches modulate AD in postmenopausal women has not been explained earlier thoroughly. Present review will enlighten all the molecular mechanisms of estrogen and estrogen replacement therapies in AD. Along‐with this, the association between estrogen, estrogen‐metabolising enzymes and ApoE protein polymorphisms will also be discussed in postmenopausal AD. Estrogen plays an important role in maintaining various physiological functions of the women's body. Estrogen deficiency due to oxidative stress, hormonal disbalance and disturbance in molecular signalling pathways such as intracellular calcium, Daxx translocation, glutaminergic excitotoxicity, voltage dependent anion and insulin like growth factor 1 receptor leads to the development of neurodegenerative diseases including Alzheimer's disease (AD). Molecular signalling works by altering the expression of estrogen receptors such as ERα &amp; ERβ and through estrogen response elements. Enormous strategies such as hormone replacement therapy, SSRMs, COMT inhibitors and ERβ agonists can be used to prevent estrogen depletion associated AD.</description><identifier>ISSN: 0953-816X</identifier><identifier>ISSN: 1460-9568</identifier><identifier>EISSN: 1460-9568</identifier><identifier>DOI: 10.1111/ejn.16360</identifier><identifier>PMID: 38726764</identifier><language>eng</language><publisher>France: Wiley Subscription Services, Inc</publisher><subject>Alzheimer Disease - drug therapy ; Alzheimer Disease - metabolism ; Alzheimer's disease ; Amyloid precursor protein ; Animals ; Apolipoprotein E ; Brain-derived neurotrophic factor ; Calcium (intracellular) ; Calcium channels (voltage-gated) ; Calcium signalling ; Cardiovascular diseases ; Daxx protein ; Enzymes ; estrogen ; Estrogen receptors ; estrogen receptors alpha and beta ; Estrogen Replacement Therapy - methods ; Estrogens ; Estrogens - metabolism ; Excitotoxicity ; Female ; Genistein ; Glutamatergic transmission ; Hormone replacement therapy ; Humans ; Intracellular signalling ; Menopause ; Molecular modelling ; molecular signalling ; Neurodegenerative diseases ; Neuromodulation ; Pathophysiology ; Phytoestrogens ; Post-menopause ; Protein transport ; Proteins ; Selective estrogen receptor modulators ; Signal Transduction - drug effects ; therapeutic target ; Xenoestrogens</subject><ispartof>The European journal of neuroscience, 2024-07, Vol.60 (1), p.3466-3490</ispartof><rights>2024 Federation of European Neuroscience Societies and John Wiley &amp; Sons Ltd.</rights><rights>2024 Federation of European Neuroscience Societies and John Wiley &amp; Sons Ltd</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c3130-c59b689de95e4f78e4bef3481aca81f8be785526fa4b32c41e3ae3d05e4cd6063</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fejn.16360$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fejn.16360$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,778,782,1414,27907,27908,45557,45558</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38726764$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Rishabh</creatorcontrib><creatorcontrib>Rohilla, Manni</creatorcontrib><creatorcontrib>Bansal, Seema</creatorcontrib><creatorcontrib>Bansal, Nitin</creatorcontrib><creatorcontrib>Chauhan, Samrat</creatorcontrib><creatorcontrib>Sharma, Sheenam</creatorcontrib><creatorcontrib>Goyal, Navjyoti</creatorcontrib><creatorcontrib>Gupta, Sumeet</creatorcontrib><title>Estrogen signalling and Alzheimer's disease: Decoding molecular mechanisms for therapeutic breakthrough</title><title>The European journal of neuroscience</title><addtitle>Eur J Neurosci</addtitle><description>In females, Alzheimer's disease (AD) incidences increases as compared to males due to estrogen deficiency after menopause. Estrogen therapy is the mainstay therapy for menopause and associated complications. Estrogen, a hormone with multifaceted physiological functions, has been implicated in AD pathophysiology. Estrogen plays a crucial role in amyloid precursor protein (APP) processing and overall neuronal health by regulating various factors such as brain‐derived neurotrophic factor (BDNF), intracellular calcium signalling, death domain‐associated protein (Daxx) translocation, glutamatergic excitotoxicity, Voltage‐Dependent Anion Channel, Insulin‐Like Growth Factor 1 Receptor, estrogen‐metabolising enzymes and apolipoprotein E (ApoE) protein polymorphisms. All these factors impact the physiology of postmenopausal women. Estrogen replacement therapies play an important treatment strategy to prevent AD after menopause. However, use of these therapies may lead to increased risks of breast cancer, venous thromboembolism and cardiovascular disease. Various therapeutic approaches have been used to mitigate the effects of estrogen on AD. These include hormone replacement therapy, Selective Estrogen Receptor Modulators (SERMs), Estrogen Receptor Beta (ERβ)‐Selective Agonists, Transdermal Estrogen Delivery, Localised Estrogen Delivery, Combination Therapies, Estrogen Metabolism Modulation and Alternative Estrogenic Compounds like genistein from soy, a notable phytoestrogen from plant sources. However, mechanism via which these approaches modulate AD in postmenopausal women has not been explained earlier thoroughly. Present review will enlighten all the molecular mechanisms of estrogen and estrogen replacement therapies in AD. Along‐with this, the association between estrogen, estrogen‐metabolising enzymes and ApoE protein polymorphisms will also be discussed in postmenopausal AD. Estrogen plays an important role in maintaining various physiological functions of the women's body. Estrogen deficiency due to oxidative stress, hormonal disbalance and disturbance in molecular signalling pathways such as intracellular calcium, Daxx translocation, glutaminergic excitotoxicity, voltage dependent anion and insulin like growth factor 1 receptor leads to the development of neurodegenerative diseases including Alzheimer's disease (AD). Molecular signalling works by altering the expression of estrogen receptors such as ERα &amp; ERβ and through estrogen response elements. Enormous strategies such as hormone replacement therapy, SSRMs, COMT inhibitors and ERβ agonists can be used to prevent estrogen depletion associated AD.</description><subject>Alzheimer Disease - drug therapy</subject><subject>Alzheimer Disease - metabolism</subject><subject>Alzheimer's disease</subject><subject>Amyloid precursor protein</subject><subject>Animals</subject><subject>Apolipoprotein E</subject><subject>Brain-derived neurotrophic factor</subject><subject>Calcium (intracellular)</subject><subject>Calcium channels (voltage-gated)</subject><subject>Calcium signalling</subject><subject>Cardiovascular diseases</subject><subject>Daxx protein</subject><subject>Enzymes</subject><subject>estrogen</subject><subject>Estrogen receptors</subject><subject>estrogen receptors alpha and beta</subject><subject>Estrogen Replacement Therapy - methods</subject><subject>Estrogens</subject><subject>Estrogens - metabolism</subject><subject>Excitotoxicity</subject><subject>Female</subject><subject>Genistein</subject><subject>Glutamatergic transmission</subject><subject>Hormone replacement therapy</subject><subject>Humans</subject><subject>Intracellular signalling</subject><subject>Menopause</subject><subject>Molecular modelling</subject><subject>molecular signalling</subject><subject>Neurodegenerative diseases</subject><subject>Neuromodulation</subject><subject>Pathophysiology</subject><subject>Phytoestrogens</subject><subject>Post-menopause</subject><subject>Protein transport</subject><subject>Proteins</subject><subject>Selective estrogen receptor modulators</subject><subject>Signal Transduction - drug effects</subject><subject>therapeutic target</subject><subject>Xenoestrogens</subject><issn>0953-816X</issn><issn>1460-9568</issn><issn>1460-9568</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp10EtLxDAUhuEgio6XhX9AAi7URTVpmjR1JzreEN0ouCtpetpmTJsxaRH99XYcdSF4Nmfz8C1ehHYpOabjncCsO6aCCbKCJjQRJMq4kKtoQjLOIknF8wbaDGFGCJEi4etog8k0FqlIJqieht67GjocTN0pa01XY9WV-Mx-NGBa8AcBlyaACnCKL0C7ciFaZ0EPVnncgm5UZ0IbcOU87hvwag5DbzQuPKiXvvFuqJtttFYpG2Dn-2-hp8vp4_l1dPdwdXN-dhdpRhmJNM8KIbMSMg5JlUpICqhYIqnSStJKFpBKzmNRqaRgsU4oMAWsJKPWpSCCbaHD5e7cu9cBQp-3JmiwVnXghpAzwlmWiphkI93_Q2du8GODhUp5mkkep6M6WirtXQgeqnzuTav8e05Jvqifj_Xzr_qj3fteHIoWyl_5k3sEJ0vwZiy8_7-UT2_vl5OfDyCPrw</recordid><startdate>202407</startdate><enddate>202407</enddate><creator>Rishabh</creator><creator>Rohilla, Manni</creator><creator>Bansal, Seema</creator><creator>Bansal, Nitin</creator><creator>Chauhan, Samrat</creator><creator>Sharma, Sheenam</creator><creator>Goyal, Navjyoti</creator><creator>Gupta, Sumeet</creator><general>Wiley Subscription Services, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QP</scope><scope>7QR</scope><scope>7TK</scope><scope>8FD</scope><scope>FR3</scope><scope>P64</scope><scope>7X8</scope></search><sort><creationdate>202407</creationdate><title>Estrogen signalling and Alzheimer's disease: Decoding molecular mechanisms for therapeutic breakthrough</title><author>Rishabh ; Rohilla, Manni ; Bansal, Seema ; Bansal, Nitin ; Chauhan, Samrat ; Sharma, Sheenam ; Goyal, Navjyoti ; Gupta, Sumeet</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3130-c59b689de95e4f78e4bef3481aca81f8be785526fa4b32c41e3ae3d05e4cd6063</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Alzheimer Disease - drug therapy</topic><topic>Alzheimer Disease - metabolism</topic><topic>Alzheimer's disease</topic><topic>Amyloid precursor protein</topic><topic>Animals</topic><topic>Apolipoprotein E</topic><topic>Brain-derived neurotrophic factor</topic><topic>Calcium (intracellular)</topic><topic>Calcium channels (voltage-gated)</topic><topic>Calcium signalling</topic><topic>Cardiovascular diseases</topic><topic>Daxx protein</topic><topic>Enzymes</topic><topic>estrogen</topic><topic>Estrogen receptors</topic><topic>estrogen receptors alpha and beta</topic><topic>Estrogen Replacement Therapy - methods</topic><topic>Estrogens</topic><topic>Estrogens - metabolism</topic><topic>Excitotoxicity</topic><topic>Female</topic><topic>Genistein</topic><topic>Glutamatergic transmission</topic><topic>Hormone replacement therapy</topic><topic>Humans</topic><topic>Intracellular signalling</topic><topic>Menopause</topic><topic>Molecular modelling</topic><topic>molecular signalling</topic><topic>Neurodegenerative diseases</topic><topic>Neuromodulation</topic><topic>Pathophysiology</topic><topic>Phytoestrogens</topic><topic>Post-menopause</topic><topic>Protein transport</topic><topic>Proteins</topic><topic>Selective estrogen receptor modulators</topic><topic>Signal Transduction - drug effects</topic><topic>therapeutic target</topic><topic>Xenoestrogens</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Rishabh</creatorcontrib><creatorcontrib>Rohilla, Manni</creatorcontrib><creatorcontrib>Bansal, Seema</creatorcontrib><creatorcontrib>Bansal, Nitin</creatorcontrib><creatorcontrib>Chauhan, Samrat</creatorcontrib><creatorcontrib>Sharma, Sheenam</creatorcontrib><creatorcontrib>Goyal, Navjyoti</creatorcontrib><creatorcontrib>Gupta, Sumeet</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Calcium &amp; Calcified Tissue Abstracts</collection><collection>Chemoreception Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>The European journal of neuroscience</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Rishabh</au><au>Rohilla, Manni</au><au>Bansal, Seema</au><au>Bansal, Nitin</au><au>Chauhan, Samrat</au><au>Sharma, Sheenam</au><au>Goyal, Navjyoti</au><au>Gupta, Sumeet</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Estrogen signalling and Alzheimer's disease: Decoding molecular mechanisms for therapeutic breakthrough</atitle><jtitle>The European journal of neuroscience</jtitle><addtitle>Eur J Neurosci</addtitle><date>2024-07</date><risdate>2024</risdate><volume>60</volume><issue>1</issue><spage>3466</spage><epage>3490</epage><pages>3466-3490</pages><issn>0953-816X</issn><issn>1460-9568</issn><eissn>1460-9568</eissn><abstract>In females, Alzheimer's disease (AD) incidences increases as compared to males due to estrogen deficiency after menopause. Estrogen therapy is the mainstay therapy for menopause and associated complications. Estrogen, a hormone with multifaceted physiological functions, has been implicated in AD pathophysiology. Estrogen plays a crucial role in amyloid precursor protein (APP) processing and overall neuronal health by regulating various factors such as brain‐derived neurotrophic factor (BDNF), intracellular calcium signalling, death domain‐associated protein (Daxx) translocation, glutamatergic excitotoxicity, Voltage‐Dependent Anion Channel, Insulin‐Like Growth Factor 1 Receptor, estrogen‐metabolising enzymes and apolipoprotein E (ApoE) protein polymorphisms. All these factors impact the physiology of postmenopausal women. Estrogen replacement therapies play an important treatment strategy to prevent AD after menopause. However, use of these therapies may lead to increased risks of breast cancer, venous thromboembolism and cardiovascular disease. Various therapeutic approaches have been used to mitigate the effects of estrogen on AD. These include hormone replacement therapy, Selective Estrogen Receptor Modulators (SERMs), Estrogen Receptor Beta (ERβ)‐Selective Agonists, Transdermal Estrogen Delivery, Localised Estrogen Delivery, Combination Therapies, Estrogen Metabolism Modulation and Alternative Estrogenic Compounds like genistein from soy, a notable phytoestrogen from plant sources. However, mechanism via which these approaches modulate AD in postmenopausal women has not been explained earlier thoroughly. Present review will enlighten all the molecular mechanisms of estrogen and estrogen replacement therapies in AD. Along‐with this, the association between estrogen, estrogen‐metabolising enzymes and ApoE protein polymorphisms will also be discussed in postmenopausal AD. Estrogen plays an important role in maintaining various physiological functions of the women's body. Estrogen deficiency due to oxidative stress, hormonal disbalance and disturbance in molecular signalling pathways such as intracellular calcium, Daxx translocation, glutaminergic excitotoxicity, voltage dependent anion and insulin like growth factor 1 receptor leads to the development of neurodegenerative diseases including Alzheimer's disease (AD). Molecular signalling works by altering the expression of estrogen receptors such as ERα &amp; ERβ and through estrogen response elements. Enormous strategies such as hormone replacement therapy, SSRMs, COMT inhibitors and ERβ agonists can be used to prevent estrogen depletion associated AD.</abstract><cop>France</cop><pub>Wiley Subscription Services, Inc</pub><pmid>38726764</pmid><doi>10.1111/ejn.16360</doi><tpages>25</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0953-816X
ispartof The European journal of neuroscience, 2024-07, Vol.60 (1), p.3466-3490
issn 0953-816X
1460-9568
1460-9568
language eng
recordid cdi_proquest_miscellaneous_3053976209
source MEDLINE; Wiley Online Library Journals Frontfile Complete
subjects Alzheimer Disease - drug therapy
Alzheimer Disease - metabolism
Alzheimer's disease
Amyloid precursor protein
Animals
Apolipoprotein E
Brain-derived neurotrophic factor
Calcium (intracellular)
Calcium channels (voltage-gated)
Calcium signalling
Cardiovascular diseases
Daxx protein
Enzymes
estrogen
Estrogen receptors
estrogen receptors alpha and beta
Estrogen Replacement Therapy - methods
Estrogens
Estrogens - metabolism
Excitotoxicity
Female
Genistein
Glutamatergic transmission
Hormone replacement therapy
Humans
Intracellular signalling
Menopause
Molecular modelling
molecular signalling
Neurodegenerative diseases
Neuromodulation
Pathophysiology
Phytoestrogens
Post-menopause
Protein transport
Proteins
Selective estrogen receptor modulators
Signal Transduction - drug effects
therapeutic target
Xenoestrogens
title Estrogen signalling and Alzheimer's disease: Decoding molecular mechanisms for therapeutic breakthrough
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-16T11%3A59%3A28IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Estrogen%20signalling%20and%20Alzheimer's%20disease:%20Decoding%20molecular%20mechanisms%20for%20therapeutic%20breakthrough&rft.jtitle=The%20European%20journal%20of%20neuroscience&rft.au=Rishabh&rft.date=2024-07&rft.volume=60&rft.issue=1&rft.spage=3466&rft.epage=3490&rft.pages=3466-3490&rft.issn=0953-816X&rft.eissn=1460-9568&rft_id=info:doi/10.1111/ejn.16360&rft_dat=%3Cproquest_cross%3E3075798527%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3075798527&rft_id=info:pmid/38726764&rfr_iscdi=true